BlueRock Therapeutics LP Graft-Related Arrhythmia Treatment Patent Application
Summary
The USPTO published patent application US20260097012A1 by BlueRock Therapeutics LP on April 9, 2026, disclosing methods of treating or preventing graft-related arrhythmia in cardiac graft patients by administering combinations of anti-arrhythmic agents including amiodarone, metoprolol, ivabradine, and mexiletine. The application was originally filed on September 27, 2023. This published application makes the invention publicly available for examination and potential licensing or competitive intelligence purposes.
What changed
The USPTO published patent application US20260097012A1 disclosing pharmaceutical compositions and methods for treating graft-related arrhythmia in cardiac graft patients. The claimed invention involves administering combinations of anti-arrhythmic agents such as amiodarone, metoprolol, ivabradine, and mexiletine to subjects receiving cardiac grafts.
For pharmaceutical and biotech companies developing cardiac therapies or cell-based treatments, this published application establishes prior art and may affect freedom-to-operate analyses. Competitors should review the claims for overlap with their own development programs. Patent monitoring systems should be updated to track prosecution of this application toward potential grant.
What to do next
- Monitor for updates on patent prosecution status
- Review claims for potential freedom-to-operate implications
- Assess competitive landscape for cardiac graft arrhythmia treatments
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR TREATING GRAFT-RELATED ARRHYTHMIA
Application US20260097012A1 Kind: A1 Apr 09, 2026
Assignee
BlueRock Therapeutics LP
Inventors
Ibrahim Domian, Rocco Romagnuolo
Abstract
Provided herein are methods of treating or preventing an arrhythmia in a cardiac graft patient, wherein the method comprises administering combinations of anti-arrhythmic agents (e.g., amiodarone, metoprolol, ivabradine, and/or mexiletine) to the subject in need thereof.
CPC Classifications
A61K 31/343 A61K 31/138 A61K 31/166 A61K 31/167 A61K 31/277 A61K 31/55 A61K 35/34 A61P 9/06
Filing Date
2023-09-27
Application No.
19115880
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.